Last updated on June 2016

An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations ("OFF" Episodes)


Brief description of study

An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Detailed Study Description

Parkinson’s disease affects about 1 million people in the United States. Up to 50% of those affected experience daily changes in performing motor activities, called “OFF” episodes. These include periods of time where your medication wears off before the next dose and your Parkinson’s disease symptoms return, a delay in the response to your Parkinson’s disease medications, a partial response to your Parkinson’s disease medications or when your Parkinson’s disease medications suddenly, unexpectedly stop working. This study is evaluating the efficacy, safety and tolerability of a drug called APL-130277, a fast-acting thin film formulation of apomorphine that is placed under the tongue and is intended to be an alternative to the injectable form of apomorphine in patients with PD who experience motor fluctuations (“OFF” episodes).

Clinical Study Identifier: TX81894

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Leigh Donharl

University of South Florida - USF Health Byrd Alzheimer's Institute
Tampa, FL USA
  Connect »